CN111869879A - 一种能够调节cyp1a1基因表达的产品 - Google Patents
一种能够调节cyp1a1基因表达的产品 Download PDFInfo
- Publication number
- CN111869879A CN111869879A CN202010662945.5A CN202010662945A CN111869879A CN 111869879 A CN111869879 A CN 111869879A CN 202010662945 A CN202010662945 A CN 202010662945A CN 111869879 A CN111869879 A CN 111869879A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus plantarum
- product
- gene expression
- regulating
- cyp1a1 gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000014509 gene expression Effects 0.000 title claims abstract description 44
- 101150055214 cyp1a1 gene Proteins 0.000 title claims abstract description 29
- 230000001105 regulatory effect Effects 0.000 title claims abstract description 19
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 82
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 82
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 82
- 244000005700 microbiome Species 0.000 claims abstract description 5
- 230000007413 intestinal health Effects 0.000 claims abstract description 4
- 239000000843 powder Substances 0.000 claims description 34
- 235000013336 milk Nutrition 0.000 claims description 19
- 239000008267 milk Substances 0.000 claims description 19
- 210000004080 milk Anatomy 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 17
- 239000007788 liquid Substances 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 13
- 238000004321 preservation Methods 0.000 claims description 12
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 11
- 235000012055 fruits and vegetables Nutrition 0.000 claims description 10
- 235000013305 food Nutrition 0.000 claims description 9
- 235000015140 cultured milk Nutrition 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 7
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 6
- 239000000654 additive Substances 0.000 claims description 5
- 230000000996 additive effect Effects 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000002502 liposome Substances 0.000 claims description 3
- 230000000813 microbial effect Effects 0.000 claims description 3
- 239000003094 microcapsule Substances 0.000 claims description 3
- 239000004005 microsphere Substances 0.000 claims description 3
- 239000002105 nanoparticle Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 235000013351 cheese Nutrition 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 abstract description 26
- FMMWHPNWAFZXNH-UHFFFAOYSA-N Benz[a]pyrene Chemical compound C1=C2C3=CC=CC=C3C=C(C=C3)C2=C2C3=CC=CC2=C1 FMMWHPNWAFZXNH-UHFFFAOYSA-N 0.000 abstract description 23
- 241000699670 Mus sp. Species 0.000 abstract description 21
- 241000699666 Mus <mouse, genus> Species 0.000 abstract description 13
- 101100275566 Homo sapiens CYP1A1 gene Proteins 0.000 abstract description 11
- 108020004999 messenger RNA Proteins 0.000 abstract description 11
- 230000006378 damage Effects 0.000 abstract description 9
- 230000001575 pathological effect Effects 0.000 abstract description 6
- 230000001580 bacterial effect Effects 0.000 description 56
- 239000001963 growth medium Substances 0.000 description 43
- 239000000243 solution Substances 0.000 description 37
- 238000012258 culturing Methods 0.000 description 23
- 235000020183 skimmed milk Nutrition 0.000 description 19
- 239000000725 suspension Substances 0.000 description 19
- 244000068988 Glycine max Species 0.000 description 17
- 235000010469 Glycine max Nutrition 0.000 description 17
- 230000004913 activation Effects 0.000 description 15
- 239000010802 sludge Substances 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- 230000003213 activating effect Effects 0.000 description 9
- 239000008103 glucose Substances 0.000 description 9
- 238000011081 inoculation Methods 0.000 description 9
- 238000009630 liquid culture Methods 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 238000000034 method Methods 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- 229940041514 candida albicans extract Drugs 0.000 description 7
- 238000004108 freeze drying Methods 0.000 description 7
- 239000008055 phosphate buffer solution Substances 0.000 description 7
- 239000012137 tryptone Substances 0.000 description 7
- 239000012138 yeast extract Substances 0.000 description 7
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 6
- 229920002774 Maltodextrin Polymers 0.000 description 6
- 239000005913 Maltodextrin Substances 0.000 description 6
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 6
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 230000007062 hydrolysis Effects 0.000 description 6
- 238000006460 hydrolysis reaction Methods 0.000 description 6
- 229940035034 maltodextrin Drugs 0.000 description 6
- 239000003223 protective agent Substances 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 229940073490 sodium glutamate Drugs 0.000 description 6
- 238000001816 cooling Methods 0.000 description 5
- 239000002285 corn oil Substances 0.000 description 5
- 235000005687 corn oil Nutrition 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 5
- 125000005575 polycyclic aromatic hydrocarbon group Chemical group 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000001514 detection method Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 229960001305 cysteine hydrochloride Drugs 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 239000002619 cytotoxin Substances 0.000 description 2
- YXVFQADLFFNVDS-UHFFFAOYSA-N diammonium citrate Chemical compound [NH4+].[NH4+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O YXVFQADLFFNVDS-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 229910052564 epsomite Inorganic materials 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 210000002175 goblet cell Anatomy 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 229910000357 manganese(II) sulfate Inorganic materials 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 230000004783 oxidative metabolism Effects 0.000 description 2
- 230000008807 pathological lesion Effects 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 235000013322 soy milk Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 239000002676 xenobiotic agent Substances 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 206010007269 Carcinogenicity Diseases 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 1
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- DQEPMTIXHXSFOR-UHFFFAOYSA-N benzo[a]pyrene diol epoxide I Chemical compound C1=C2C(C3OC3C(C3O)O)=C3C=C(C=C3)C2=C2C3=CC=CC2=C1 DQEPMTIXHXSFOR-UHFFFAOYSA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000003034 coal gas Substances 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000021022 fresh fruits Nutrition 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 229940004208 lactobacillus bulgaricus Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 239000003345 natural gas Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003209 petroleum derivative Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000010092 rubber production Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C11/00—Milk substitutes, e.g. coffee whitener compositions
- A23C11/02—Milk substitutes, e.g. coffee whitener compositions containing at least one non-milk component as source of fats or proteins
- A23C11/10—Milk substitutes, e.g. coffee whitener compositions containing at least one non-milk component as source of fats or proteins containing or not lactose but no other milk components as source of fats, carbohydrates or proteins
- A23C11/103—Milk substitutes, e.g. coffee whitener compositions containing at least one non-milk component as source of fats or proteins containing or not lactose but no other milk components as source of fats, carbohydrates or proteins containing only proteins from pulses, oilseeds or nuts, e.g. nut milk
- A23C11/106—Addition of, or treatment with, microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C19/00—Cheese; Cheese preparations; Making thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/16—Agglomerating or granulating milk powder; Making instant milk powder; Products obtained thereby
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
- A23L2/382—Other non-alcoholic beverages fermented
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nutrition Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开了一种能够调节CYP1A1基因表达的产品,属于微生物技术领域。本发明提供了一种产品,此产品的有效成分为植物乳杆菌(Lactobacillus plantarum)CCFM8661,此植物乳杆菌CCFM8661能够有效调节人体CYP1A1基因的表达,具体体现在:(1)显著改善苯并芘暴露小鼠结肠组织的病理损伤;(2)显著改善苯并芘暴露小鼠结肠中CYP1A1基因的mRNA表达量,因此,本发明的产品在调节人体CYP1A1基因表达以及改善人体肠道健康中具有极高的应用前景。
Description
技术领域
本发明涉及一种能够调节CYP1A1基因表达的产品,属于微生物技术领域。
背景技术
CYP1A1基因编码P450系氧化代谢酶,而P450系氧化代谢酶能将多种异生素(xenobiotics)转化为细胞毒素或者有机体诱变物质的衍生物。例如,苯并芘在P450系氧化代谢酶的代谢下会转化为具有高度致癌性的物质7,8-二羟-9,10-环氧苯并芘(7,8-dihydroxybenzopyrene-9,10-oxide,BPDE);多环芳烃(polycyclic aromatichydrocarbons,PAH)在P450系氧化代谢酶的代谢下会转化为细胞毒素或其他致癌物质。除此以外,P450系氧化代谢酶还会介导雌激素转化为儿茶酚雌激素,而后者具有致癌性。可见,长期保持人体CYP1A1基因的表达量处于低水平对保持人体健康十分重要。
但是,环境中可诱导人体CYP1A1基因大量表达的物质是广泛存在的,例如,工业生产和生活过程中煤炭、石油和天然气等燃料不完全燃烧产生的废气(包括汽车尾气、橡胶生产以及吸烟产生的烟气等)中就富含多环芳烃等可诱导人体CYP1A1基因大量表达的物质。可见,降低人体因多环芳烃暴露等所导致的CYP1A1基因表达量异常升高并使其处于低水平很难实现。
因此,急需找到一种可调节人体CYP1A1基因表达量,使其长期处于低水平的产品。
发明内容
[技术问题]
本发明要解决的技术问题是提供一种可调节人体CYP1A1基因表达的产品。
[技术方案]
为解决上述问题,本发明提供了一种调节CYP1A1基因表达的产品,所述产品含有植物乳杆菌CCFM8661;所述植物乳杆菌CCFM8661保藏于广东省微生物菌种保藏中心,保藏编号为CGMCC No.5494,保藏日期为2011年11月29日。
本发明的一种实施方式中,所述产品中,植物乳杆菌CCFM8661的活菌数为不低于1×106CFU/mL或1×106CFU/g。
本发明的一种实施方式中,所述产品中包括食品或药物。
本发明的一种实施方式中,所述食品包括发酵果蔬、发酵乳、乳酪、含乳饮料、乳粉或其他含有植物乳杆菌的食品。
本发明的一种实施方式中,所述药物含有植物乳杆菌CCFM8661、药物载体和/或药用辅料。
本发明的一种实施方式中,所述药物载体包含微囊、微球、纳米粒和/或脂质体。
本发明的一种实施方式中,所述药用辅料包含赋形剂和/或附加剂。
本发明的一种实施方式中,所述赋形剂包含溶剂、抛射剂、增溶剂、助溶剂、乳化剂、着色剂、吸收剂、稀释剂、絮凝剂、反絮凝剂、助滤剂和/或释放阻滞剂。
本发明的一种实施方式中,所述附加剂包含微晶纤维素、羟丙基甲基纤维素和/或精制卵磷脂。
本发明的一种实施方式中,所述药物的剂型为粉剂、颗粒剂、胶囊剂、片剂、丸剂或口服液。
本发明还提供了植物乳杆菌CCFM8661在调节CYP1A1基因表达中的应用,所述植物乳杆菌CCFM8661保藏于广东省微生物菌种保藏中心,保藏编号为CGMCC No.5494,保藏日期为2011年11月29日。
本发明还提供了植物乳杆菌CCFM8661在制备改善肠道健康的药物中的应用,所述植物乳杆菌CCFM8661保藏于广东省微生物菌种保藏中心,保藏编号为CGMCC No.5494,保藏日期为2011年11月29日。
本发明的一种实施方式中,所述药物中,植物乳杆菌CCFM8661的活菌数为不低于1×106CFU/mL或1×106CFU/g。
本发明的一种实施方式中,所述药物含有植物乳杆菌CCFM8661、药物载体和/或药用辅料。
本发明的一种实施方式中,所述药物载体包含微囊、微球、纳米粒和/或脂质体。
本发明的一种实施方式中,所述药用辅料包含赋形剂和/或附加剂。
本发明的一种实施方式中,所述赋形剂包含溶剂、抛射剂、增溶剂、助溶剂、乳化剂、着色剂、吸收剂、稀释剂、絮凝剂、反絮凝剂、助滤剂和/或释放阻滞剂。
本发明的一种实施方式中,所述附加剂包含微晶纤维素、羟丙基甲基纤维素和/或精制卵磷脂。
本发明的一种实施方式中,所述药物的剂型为粉剂、颗粒剂、胶囊剂、片剂、丸剂或口服液。
有益效果:
本发明提供了一种产品,此产品的有效成分为植物乳杆菌(Lactobacillusplantarum)CCFM8661,此植物乳杆菌CCFM8661能够有效调节人体CYP1A1基因的表达,具体体现在:
(1)显著改善苯并芘暴露小鼠结肠组织的病理损伤;
(2)显著改善苯并芘暴露小鼠结肠中CYP1A1基因的mRNA表达量,
因此,本发明的产品在调节人体CYP1A1基因表达以及改善人体肠道健康中具有极高的应用前景。
附图说明
图1:载体对照组小鼠结肠组织的病理损伤情况。
图2:模型组小鼠结肠组织的病理损伤情况。
图3:植物乳杆菌CCFM382干预小鼠结肠组织的病理损伤情况。
图4:植物乳杆菌CCFM8661干预小鼠结肠组织的病理损伤情况。
图5:不同组小鼠结肠中CYP1A1基因的mRNA表达量。
具体实施方式
苯并芘是多环芳烃的一种,苯并芘暴露可显著提高人体CYP1A1基因的表达量,因此,下述实施例中以苯并芘暴露小鼠作为模型,考察不同植物乳杆菌对CYP1A1基因表达的影响。
下述实施例中涉及的植物乳杆菌(Lactobacillus plantarum)CCFM8661的保藏编号为CGMCC No.5494,记载于公开号为CN102586148A的专利申请文本中;下述实施例中涉及的植物乳杆菌(Lactobacillus plantarum)CCFM382的保藏编号为CGMCC No.9734,记载于公开号为CN104357349A的专利申请文本中;下述实施例中涉及的SPF级8周龄雄性BALB/C小鼠购自斯莱克实验动物有限公司;下述实施例中涉及的脱脂乳购自福麦斯生物技术有限公司;下述实施例中涉及的玉米油购自阿拉丁生化科技股份有限公司;下述实施例中涉及的脱脂奶粉购自纽瑞兹食品有限公司;下述实施例中涉及的苯并芘购自美国sigma公司。
下述实施例中涉及的培养基如下:
MRS固体培养基(g/L):蛋白胨10g/L、牛肉膏10g/L、葡萄糖20g/L、乙酸钠2g/L、酵母粉5g/L、柠檬酸氢二铵2g/L、K2PO4·3H2O 2.6g/L、MgSO4·7H2O 0.1g/L、MnSO4 0.05g/L、吐温80 1mL/L、琼脂20g/L、半胱氨酸氨酸盐0.5g/L,pH为6.8。
MRS液体培养基(g/L):蛋白胨10g/L、牛肉膏10g/L、葡萄糖20g/L、乙酸钠2g/L、酵母粉5g/L、柠檬酸氢二铵2g/L、K2PO4·3H2O 2.6g/L、MgSO4·7H2O 0.1g/L、MnSO4 0.05g/L、吐温80 1mL/L、半胱氨酸氨酸盐0.5g/L,pH为6.8。
下述实施例中涉及的检测方法如下:
活菌数的检测方法:采用国标《GB 4789.35-2016食品安全国家标准食品微生物学检测乳酸菌检测》。
下述实施例中涉及的植物乳杆菌菌悬液的制备方法如下:
将植物乳杆菌菌液划线于MRS固体培养基上,37℃条件下培养48h,得到单菌落;挑取单菌落接种于MRS液体培养基中,37℃条件下培养18h进行活化,连续活化两代,得到活化液;将活化液按2%(v/v)的接种量接种于MRS液体培养基中,37℃条件下培养18h,得到菌液;将菌液经5000g离心15min,得到植物乳杆菌菌体;将植物乳杆菌菌体经pH为7.2的生理盐水洗涤3次后重悬于浓度为130g/L的脱脂奶粉溶液中至菌浓度为1.5×1010CFU/mL,得到菌悬液,将菌悬液于-80℃下保存待用。
实施例1:植物乳杆菌CCFM8661对CYP1A1基因表达的影响
具体步骤如下:
1、实验方法
取32只SPF级8周龄雄性BALB/C小鼠,随机分为4组,每组8只,4组分别为:载体对照组(Control)、模型组(Modle)、CCFM382干预组和CCFM8661干预组。所有小鼠饲养于25±2℃、相对湿50±5%、12h光照/12h黑暗的标准化实验室中,适应性喂养一周后开始实验。
实验共35天:实验期间,载体对照组小鼠按照50mg/kg.bw的剂量每天灌胃玉米油,并且,按照0.2mL/只的剂量每天灌胃浓度为130g/L的脱脂奶粉溶液;模型组小鼠按照50mg/kg.bw的剂量每天灌胃含有苯并芘溶液(苯并芘溶液是通过将苯并芘溶于玉米油得到的),并且,按照0.2mL/只的剂量每天灌胃浓度为130g/L的脱脂奶粉溶液;CCFM382干预组小鼠按照50mg/kg.bw的剂量每天灌胃含有苯并芘溶液(苯并芘溶液是通过将苯并芘溶于玉米油得到的),并且,按照0.2mL/只的剂量每天灌胃植物乳杆菌CCFM382菌悬液;CCFM8661干预组小鼠按照50mg/kg.bw的剂量每天灌胃含有苯并芘溶液(苯并芘溶液是通过将苯并芘溶于玉米油得到的),并且,按照0.2mL/只的剂量每天灌胃植物乳杆菌CCFM8661菌悬液。灌胃结束后处死所有小鼠,取部分小鼠结肠组织置于10%福尔马林溶液中用于组织切片观察,剩下的结肠分段置于2mL离心管中置于-80℃冰箱。
2、实验结果
2.1、不同植物乳杆菌对苯并芘暴露小鼠结肠组织病理损伤情况的影响
取HE染色的结肠组织切片,在光学显微镜下观察组织形态变化。结肠组织切片观察结果如图1-4所示,载体对照组小鼠结肠粘膜上皮细胞完整,隐窝正常,腺体排列整齐有序,且无溃疡存在;与载体对照组相比,模型组小鼠则出现了严重的结肠损伤和急性结肠炎症状,伴随溃疡,隐窝破坏,以及严重的炎性;灌胃植物乳杆菌CCFM8661后,苯并芘暴露小鼠结肠粘膜未出现明显糜烂,而且隐窝完整,腺体排列整齐,杯状细胞完整,与载体对照组结肠组织形态接近;植物乳杆菌CCFM382改善苯并芘暴露小鼠结肠组织病理损伤情况的效果则明显不如植物乳杆菌CCFM8661。以上实验结果表明,植物乳杆菌CCFM8661能够很好地保护结肠粘膜的完整性,减少炎症对结肠的损伤。
2.2、不同植物乳杆菌对苯并芘暴露小鼠结肠中CYP1A1基因mRNA表达量的影响
CYP1A1和内参基因GAPDH的扩增引物如表1所示,CYP1A1的mRNA表达水平以相对于载体对照组表达水平显示。
小鼠结肠中CYP1A1基因mRNA表达量的检测结果如图5所示,与载体对照组相比,模型组小鼠结肠中CYP1A1基因mRNA表达量明显上升(较载体对照组上升了625%);与模型组相比,灌胃植物乳杆菌CCFM8661后,苯并芘暴露小鼠结肠中CYP1A1基因mRNA表达量明显下降(较模型组下降了422%);植物乳杆菌CCFM382则不能降低苯并芘暴露小鼠结肠中CYP1A1基因mRNA表达量(较模型组提高了67%)。以上实验结果表明,植物乳杆菌CCFM8661能够很好地调节苯并芘暴露小鼠结肠中CYP1A1基因mRNA表达量,使其保持在一个较低的水平。
表1 RT-PCR引物序列
实施例2:植物乳杆菌CCFM8661的应用
具体步骤如下:
植物乳杆菌CCFM8661可用于制备菌粉,菌粉的具体制备过程如下:
植物乳杆菌CCFM8661划线于MRS固体培养基上,37℃条件下培养48h,得到单菌落;挑取单菌落接种于MRS液体培养基中,37℃条件下培养18h进行活化,连续活化两代,得到活化液;将活化液按2%(v/v)的接种量接种于培养基中,37℃条件下培养18h,得到菌液;将菌液经5000g离心15min,得到菌泥;将菌泥用pH为7.2的磷酸盐缓冲液清洗3次后用保护剂重悬至浓度为1×1010CFU/mL,得到菌悬液;将菌悬液在温度37℃下预培养60min后冻干,得到植物乳杆菌CCFM8661菌粉;
其中,培养基的制备方法为:使用以培养基总重量计87.7%的水将10%酶水解脱脂乳、0.5%葡萄糖、1.5%胰蛋白胨与0.3%酵母浸膏溶解,然后调整其pH为6.8,得到培养基;
保护剂的成分包含:100g/L脱脂奶粉、30mL/L甘油、100g/L麦芽糊精、150g/L海藻糖和10g/LL-谷氨酸钠。
实施例3:植物乳杆菌CCFM8661的应用
具体步骤如下:
植物乳杆菌CCFM8661可用于制备牛乳,发酵乳的具体制备过程如下:
植物乳杆菌CCFM8661划线于MRS固体培养基上,37℃条件下培养48h,得到单菌落;挑取单菌落接种于MRS液体培养基中,37℃条件下培养18h进行活化,连续活化两代,得到活化液;将活化液按2%(v/v)的接种量接种于培养基中,37℃条件下培养18h,得到菌液;将菌液经5000g离心15min,得到菌泥;将菌泥用pH为7.2的磷酸盐缓冲液清洗3次后用保护剂重悬至浓度为1×1010CFU/mL,得到菌悬液;将菌悬液在温度37℃下预培养60min后冻干,得到植物乳杆菌CCFM8661菌粉;
其中,培养基的制备方法为:使用以培养基总重量计87.7%的水将10%酶水解脱脂乳、0.5%葡萄糖、1.5%胰蛋白胨与0.3%酵母浸膏溶解,然后调整其pH为6.8,得到培养基;
保护剂的成分包含:100g/L脱脂奶粉、30mL/L甘油、100g/L麦芽糊精、150g/L海藻糖和10g/LL-谷氨酸钠。
将脱脂奶在95℃热杀菌20min后冷却至4℃,得到原料;在原料中添加植物乳杆菌CCFM8661菌粉至浓度为不低于1×106CFU/mL,得到牛乳。
实施例4:植物乳杆菌CCFM8661的应用
具体步骤如下:
植物乳杆菌CCFM8661可用于制备豆奶,豆奶的具体制备过程如下:
植物乳杆菌CCFM8661划线于MRS固体培养基上,37℃条件下培养48h,得到单菌落;挑取单菌落接种于MRS液体培养基中,37℃条件下培养18h进行活化,连续活化两代,得到活化液;将活化液按2%(v/v)的接种量接种于培养基中,37℃条件下培养18h,得到菌液;将菌液经5000g离心15min,得到菌泥;将菌泥用pH为7.2的磷酸盐缓冲液清洗3次后用保护剂重悬至浓度为1×1010CFU/mL,得到菌悬液;将菌悬液在温度37℃下预培养60min后冻干,得到植物乳杆菌CCFM8661菌粉;
其中,培养基的制备方法为:使用以培养基总重量计87.7%的水将10%酶水解脱脂乳、0.5%葡萄糖、1.5%胰蛋白胨与0.3%酵母浸膏溶解,然后调整其pH为6.8,得到培养基;
保护剂的成分包含:100g/L脱脂奶粉、30mL/L甘油、100g/L麦芽糊精、150g/L海藻糖和10g/LL-谷氨酸钠。
将大豆在温度80℃下浸泡2h后去除大豆皮,得到去皮大豆;将去皮大豆沥去浸泡水后加沸水磨浆,得到豆浆;将豆浆在高于80℃的温度条件下保温12min,得到熟豆浆;将熟豆浆用150目筛网过滤后离心分离,得到粗豆奶;将粗豆奶加热到温度140~150℃后迅速导入真空冷却室进行抽真空,使得粗豆奶中的异味物质随着水蒸汽迅速排出,得到熟豆奶;将熟豆奶降温至约37℃后在熟豆奶中添加植物乳杆菌CCFM8661菌粉至浓度为不低于1×106CFU/mL,得到豆奶。
实施例5:植物乳杆菌CCFM8661的应用
具体步骤如下:
植物乳杆菌CCFM8661可用于制备果蔬饮料,果蔬饮料的具体制备过程如下:
植物乳杆菌CCFM8661划线于MRS固体培养基上,37℃条件下培养48h,得到单菌落;挑取单菌落接种于MRS液体培养基中,37℃条件下培养18h进行活化,连续活化两代,得到活化液;将活化液按2%(v/v)的接种量接种于培养基中,37℃条件下培养18h,得到菌液;将菌液经5000g离心15min,得到菌泥;将菌泥用pH为7.2的磷酸盐缓冲液清洗3次后用保护剂重悬至浓度为1×1010CFU/mL,得到菌悬液;将菌悬液在温度37℃下预培养60min后冻干,得到植物乳杆菌CCFM8661菌粉;
其中,培养基的制备方法为:使用以培养基总重量计87.7%的水将10%酶水解脱脂乳、0.5%葡萄糖、1.5%胰蛋白胨与0.3%酵母浸膏溶解,然后调整其pH为6.8,得到培养基;
保护剂的成分包含:100g/L脱脂奶粉、30mL/L甘油、100g/L麦芽糊精、150g/L海藻糖和10g/LL-谷氨酸钠。
将新鲜水果和蔬菜洗净后榨汁,得到果蔬汁;将果蔬汁在温度140℃下高温热杀菌2秒,得到杀菌后的果蔬汁;将杀菌后的果蔬汁降温至约37℃后在杀菌后的果蔬汁中添加植物乳杆菌CCFM8661菌粉至浓度为不低于1×106CFU/mL,得到果蔬饮料。
实施例6:植物乳杆菌CCFM8661的应用
具体步骤如下:
植物乳杆菌CCFM8661可用于制备胶囊制品,胶囊制品的具体制备过程如下
植物乳杆菌CCFM8661划线于MRS固体培养基上,37℃条件下培养48h,得到单菌落;挑取单菌落接种于MRS液体培养基中,37℃条件下培养18h进行活化,连续活化两代,得到活化液;将活化液按2%(v/v)的接种量接种于培养基中,37℃条件下培养18h,得到菌液;将菌液经5000g离心15min,得到菌泥;将菌泥用pH为7.2的磷酸盐缓冲液清洗3次后用保护剂重悬至浓度为1×1010CFU/mL,得到菌悬液;菌悬液添加至浓度为30g/L的海藻酸钠溶液中至浓度为2×109CFU/mL后,充分搅拌,使得植物乳杆菌CCFM8661的细胞均匀地分散于海藻酸钠溶液中,得到混合液;将混合液挤压到浓度为20g/L的氯化钙溶液中形成胶粒;待形成的胶粒静止固化30min后,过滤收集胶粒;将收集得到的胶粒进行冷冻干燥48h,得到粉剂;将粉剂装入到药用胶囊中,得到胶囊制品;
其中,培养基的制备方法为:使用以培养基总重量计87.7%的水将10%酶水解脱脂乳、0.5%葡萄糖、1.5%胰蛋白胨与0.3%酵母浸膏溶解,然后调整其pH为6.8,得到培养基。
实施例7:植物乳杆菌CCFM8661的应用
具体步骤如下:
植物乳杆菌CCFM8661可用于制备发酵乳,发酵乳的具体制备过程如下:
植物乳杆菌CCFM8661划线于MRS固体培养基上,37℃条件下培养48h,得到单菌落;挑取单菌落接种于MRS液体培养基中,37℃条件下培养18h进行活化,连续活化两代,得到活化液;将活化液按2%(v/v)的接种量接种于培养基中,37℃条件下培养18h,得到菌液;将菌液经5000g离心15min,得到菌泥;将菌泥用pH为7.2的磷酸盐缓冲液清洗3次后用保护剂重悬至浓度为1×1010CFU/mL,得到菌悬液;将菌悬液在温度37℃下预培养60min后冻干,得到植物乳杆菌CCFM8661菌粉;
其中,培养基的制备方法为:使用以培养基总重量计87.7%的水将10%酶水解脱脂乳、0.5%葡萄糖、1.5%胰蛋白胨与0.3%酵母浸膏溶解,然后调整其pH为6.8,得到培养基;
保护剂的成分包含:100g/L脱脂奶粉、30mL/L甘油、100g/L麦芽糊精、150g/L海藻糖和10g/LL-谷氨酸钠。
将植物乳杆菌CCFM8661菌粉与商业干粉发酵剂保加利亚乳杆菌和商业干粉发酵剂嗜热链球菌按照质量比1:1:1的比例混合,得到发酵剂;将糖添加至鲜奶中至浓度为50g/L,得到混合液;将混合液在65℃、20MPa的条件下进行均质后在95℃下保温杀菌5min,得到发酵原料;将发酵原料降温至35℃后以0.03%(v/v)的接种量将发酵剂接种至发酵原料中,于35℃下保温发酵16h,得到发酵乳;将发酵乳于42℃下放置4h进行凝乳后,在4℃下冷藏24h进行后熟,得到发酵乳成品。
实施例8:植物乳杆菌CCFM8661的应用
具体步骤如下:
植物乳杆菌CCFM8661可用于制备片剂,片剂的具体制备过程如下:
植物乳杆菌CCFM8661划线于MRS固体培养基上,37℃条件下培养48h,得到单菌落;挑取单菌落接种于MRS液体培养基中,37℃条件下培养18h进行活化,连续活化两代,得到活化液;将活化液按2%(v/v)的接种量接种于培养基中,37℃条件下培养18h,得到菌液;将菌液经5000g离心15min,得到菌泥;将菌泥用pH为7.2的磷酸盐缓冲液清洗3次后用保护剂重悬至浓度为1×1010CFU/mL,得到菌悬液;将菌悬液在温度37℃下预培养60min后冻干,得到植物乳杆菌CCFM8661菌粉;
其中,培养基的制备方法为:使用以培养基总重量计87.7%的水将10%酶水解脱脂乳、0.5%葡萄糖、1.5%胰蛋白胨与0.3%酵母浸膏溶解,然后调整其pH为6.8,得到培养基;
保护剂的成分包含:100g/L脱脂奶粉、30mL/L甘油、100g/L麦芽糊精、150g/L海藻糖和10g/LL-谷氨酸钠。
称取植物乳杆菌CCFM8661菌粉25.7重量份、淀粉55.0重量份、纤维素衍生物4.5重量份、羧甲基淀粉钠12.0重量份、滑石粉0.8重量份、蔗糖1.0重量份与水1.0重量份,得到原材料;将原材料混合,得到湿颗粒;将湿颗粒用中南制药机械厂的压片机进行压片后使用青州市益康中药机械有限公司的小型药物干燥机进行干燥,得到片剂。
虽然本发明已以较佳实施例公开如上,但其并非用以限定本发明,任何熟悉此技术的人,在不脱离本发明的精神和范围内,都可做各种的改动与修饰,因此本发明的保护范围应该以权利要求书所界定的为准。
序列表
<110> 江南大学
<120> 一种能够调节CYP1A1基因表达的产品
<160> 4
<170> PatentIn version 3.3
<210> 1
<211> 20
<212> DNA
<213> 人工序列
<400> 1
cctcatgtac ctggtaacca 20
<210> 2
<211> 20
<212> DNA
<213> 人工序列
<400> 2
aaggatgaat gccggaaggt 20
<210> 3
<211> 19
<212> DNA
<213> 人工序列
<400> 3
tgcaccacca actgcttag 19
<210> 4
<211> 18
<212> DNA
<213> 人工序列
<400> 4
gatgcaggga tgatgttc 18
Claims (10)
1.一种调节CYP1A1基因表达的产品,其特征在于,所述产品含有植物乳杆菌;所述植物乳杆菌保藏于广东省微生物菌种保藏中心,保藏编号为CGMCC No.5494,保藏日期为2011年11月29日。
2.如权利要求1所述的一种调节CYP1A1基因表达的产品,其特征在于,所述产品中,植物乳杆菌的活菌数为不低于1×106CFU/mL或1×106CFU/g。
3.如权利要求1或2所述的一种调节CYP1A1基因表达的产品,其特征在于,所述产品中包括食品或药物。
4.如权利要求3所述的一种调节CYP1A1基因表达的产品,其特征在于,所述食品包括发酵果蔬、发酵乳、乳酪、含乳饮料、乳粉或其他含有植物乳杆菌的食品。
5.如权利要求3所述的一种调节CYP1A1基因表达的产品,其特征在于,所述药物含有植物乳杆菌、药物载体和/或药用辅料。
6.如权利要求5所述的一种调节CYP1A1基因表达的产品,其特征在于,所述药物载体包含微囊、微球、纳米粒和/或脂质体。
7.如权利要求5或6所述的一种调节CYP1A1基因表达的产品,其特征在于,所述药用辅料包含赋形剂和/或附加剂。
8.如权利要求5-7任一项所述的一种调节CYP1A1基因表达的产品,其特征在于,所述药物的剂型为粉剂、颗粒剂、胶囊剂、片剂、丸剂或口服液。
9.植物乳杆菌在调节CYP1A1基因表达中的应用,其特征在于,所述植物乳杆菌保藏于广东省微生物菌种保藏中心,保藏编号为CGMCC No.5494,保藏日期为2011年11月29日。
10.植物乳杆菌在制备改善肠道健康的药物中的应用,其特征在于,所述植物乳杆菌保藏于广东省微生物菌种保藏中心,保藏编号为CGMCC No.5494,保藏日期为2011年11月29日。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010662945.5A CN111869879B (zh) | 2020-07-10 | 2020-07-10 | 一种能够调节cyp1a1基因表达的产品 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010662945.5A CN111869879B (zh) | 2020-07-10 | 2020-07-10 | 一种能够调节cyp1a1基因表达的产品 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111869879A true CN111869879A (zh) | 2020-11-03 |
CN111869879B CN111869879B (zh) | 2023-04-28 |
Family
ID=73150025
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010662945.5A Active CN111869879B (zh) | 2020-07-10 | 2020-07-10 | 一种能够调节cyp1a1基因表达的产品 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111869879B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111826312A (zh) * | 2020-07-10 | 2020-10-27 | 江南大学 | 一株可缓解苯并芘暴露的鼠李糖乳杆菌及其应用 |
-
2020
- 2020-07-10 CN CN202010662945.5A patent/CN111869879B/zh active Active
Non-Patent Citations (1)
Title |
---|
何欢: "植物乳杆菌121缓解小鼠经口暴露苯并芘毒性探究", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111826312A (zh) * | 2020-07-10 | 2020-10-27 | 江南大学 | 一株可缓解苯并芘暴露的鼠李糖乳杆菌及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN111869879B (zh) | 2023-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111607538B (zh) | 一株鼠李糖乳杆菌及其在抑制幽门螺杆菌中的应用 | |
CN112322528B (zh) | 一株可干预代谢综合征的鼠李糖乳杆菌及应用 | |
CN108823125A (zh) | 一种治疗睡眠障碍益生菌制剂的生产方法及应用 | |
CN112322527A (zh) | 一株可干预代谢综合征的罗伊氏乳杆菌及应用 | |
CN113403231B (zh) | 一株可干预代谢综合征的罗伊氏乳杆菌ccfm1178及应用 | |
CN109588726B (zh) | 一种用于改善睡眠的干酪乳杆菌组合物及其制备方法 | |
CN113549567B (zh) | 一株具有促排便功能的鼠李糖乳杆菌nsl0401及其应用 | |
CN113337431A (zh) | 一株抑制幽门螺杆菌的罗伊氏乳杆菌nsl0501及其生物菌剂和应用 | |
CN111548970A (zh) | 一株能够预防和/或治疗幽门螺杆菌感染的卷曲乳杆菌 | |
CN109609420A (zh) | 一种抗幽门螺旋杆菌的益生菌组合物及其制备方法 | |
CN111690571B (zh) | 一株可清除丙烯酰胺的植物乳杆菌及其应用 | |
CN111471626A (zh) | 一株能够抑制幽门螺杆菌的瑞士乳杆菌及其应用 | |
CN111826312B (zh) | 一株可缓解苯并芘暴露的鼠李糖乳杆菌及其应用 | |
CN113122472B (zh) | 一株能够保护肠道通透性的普通拟杆菌及其应用 | |
CN111560325B (zh) | 一株能够调节肠道紧密连接蛋白的发酵乳杆菌及其应用 | |
CN111869879B (zh) | 一种能够调节cyp1a1基因表达的产品 | |
CN113068837B (zh) | 一株可清除壬基酚并缓解其导致的中毒症状的长双歧杆菌 | |
CN109924507A (zh) | 一种调理情绪的益生菌组合物及其制备方法 | |
CN111869735B (zh) | 一种用于预防和/或治疗苯并芘暴露的产品 | |
CN109846044B (zh) | 具有改善记忆、提高免疫力的益生菌组合物及其制备方法 | |
CN109757730B (zh) | 一种具有降血脂、血压以及血糖的组合物及其制备方法 | |
CN111603489A (zh) | 一种改善便秘的菌剂及其制备方法 | |
CN116622559B (zh) | 一种产乙醛脱氢酶的干酪乳杆菌、解酒益生菌组合物及其制备方法 | |
CN109700033B (zh) | 一种调节肠道、预防便秘的益生菌组合物及其制备方法 | |
CN113234619B (zh) | 一株两歧双歧杆菌及其在缓解肠道损伤中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |